We’re pleased to see Bedrocan share the news of the Therapeutic Goods Administration (TGA) approval for the SyqeAir inhaler in Australia. The article titled “SyqeAir inhaler approved by the Therapeutic Goods Administration (TGA)” covers this regulatory milestone, which marks a significant step forward in expanding access to our metered, inhaled medical cannabis treatment in global markets.
The publication reflects our continued collaboration with Bedrocan, whose pharmaceutical-grade cannabis is used inside the SyqeAir Cartridge, and our shared focus on delivering high standards of quality, consistency, and patient care.
